Previous 10 | Next 10 |
2024-06-10 13:25:30 ET Summary Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye dis...
2024-06-07 15:00:58 ET More on the markets Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) SPY: 2 Options To Balance Out A Highly Concentrated Index Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity Citi – ...
2024-06-07 07:59:30 ET More on AbbVie AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered AbbVie succeeds in mid-sta...
2024-06-06 20:59:58 ET Summary The Schwab U.S. Dividend Equity ETF has performed reasonably well over the years. However it has underperformed a similar strategy, which is buying a diversified portfolio of Dividend Aristocrat stocks. The Dividend Aristocrats have beaten the S&...
2024-06-06 09:08:10 ET More on AbbVie AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered AbbVie doses first patient...
2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer PR Newswire PICCOLO trial met its primary endpoint of objective ...
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin PR Newswire Allē Members Can Celebrate with Double Points and Enter for a Chance to Win $5,000 IRVINE, Calif. , June 6, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie comp...
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers PR Newswire The submission period is now open to individuals living with migraine for the new AbbVie Migraine Career Catalyst Award™ contest, awarding winners with a...
2024-06-05 11:25:00 ET Summary In May, we received a dividend income total of $1,664.04. Consumers are still strong, but earnings have been mixed, to say the least. I received 6 more dividend increases in May 2024, consistent with last month. This is what dividend in...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 08:25:00 ET Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing terribly well. In these situations, there are opportunities for investors to...
2024-07-14 04:27:00 ET The broader stock market benchmarks keep reaching new heights, but the S&P 500 index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of reliable dividend-paying stocks that look like bargains. Shares ...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis PR Newswire Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endp...